Ортоцид

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Ортоцид

What is Ортоцид? (Teicoplanin)

Ортоцид is a specialized, reserved antibiotic used primarily for treating serious bacterial infections, particularly those caused by resilient Gram-positive bacteria. It is defined by its targeted action and distinct chemical structure.

Property Description
Active ingredient Teicoplanin
Form Sterile powder for injection/infusion
Pharmacological class Glycopeptide Antibiotic
Origin Semisynthetic (derived from bacteria)

What Type of Antibiotic is Ортоцид (Teicoplanin)?

The active substance in Ортоцид is Teicoplanin, officially classified as a glycopeptide antibacterial agent. Teicoplanin is a semisynthetic lipoglycopeptide, meaning its complex structure is derived from a natural source—the bacterium Actinoplanes teichomyceticus—and then chemically refined for pharmaceutical use. This specific chemical nature relates to its utility in hospital settings against complex infections. The drug is typically reserved as a prescription-only medication (Rx status) due to its specialized role in treating severe conditions, such as those caused by resistant organisms.

Composition and General Purpose

Ортоцид is a single-ingredient product, and it is supplied as a sterile powder for solution for injection or infusion, which is a freeze-dried mass that must be mixed with a solvent before use. This solid form is administered via the Intravenous (IV) or Intramuscular (IM) route under strict medical supervision. Its general purpose is highly specialized: to serve as a critical defense against serious infections caused by specific, difficult-to-treat Gram-positive bacteria, notably including strains resistant to other drugs, such as Methicillin-resistant Staphylococcus aureus (MRSA). The drug’s bactericidal effect provides an important treatment option for severe and complicated bacterial illnesses, ensuring definitive pathogen elimination is achieved.

Advertisements

What side effects are possible with Ортоцид?

Possible side effects and safety information

The safety profile of Ортоцид (Teicoplanin), a glycopeptide antibiotic, is categorized by regulatory bodies based on the frequency and the body system affected. These classifications highlight potential adverse reactions across several System-Organ Classes (SOCs), most notably the renal (kidney), otic (ear), and haematological (blood) systems.

Adverse effects are documented using official frequency categories derived from clinical data:

  • Common effects (affecting 1 to 10 users in 100) often involve skin reactions such as rash, erythema, and pruritus (itching), alongside localized pain at the injection site and elevated blood creatinine levels.
  • Uncommon effects include dizziness, headache, diarrhea, and symptoms related to potential ototoxicity like hearing loss, tinnitus, or vertigo. Haematological changes such as thrombocytopenia and leukopenia are also listed in this category.

Rare but serious adverse reactions are formally documented and include acute kidney failure (a form of nephrotoxicity), severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), anaphylactic reactions, and the blood disorder agranulocytosis.

Official regulatory information requires specific safety considerations for certain patient groups. Individuals with pre-existing renal impairment and older adults are noted to have an increased risk of toxicity, specifically nephrotoxicity and ototoxicity. Consequently, the label mandates frequent monitoring of renal function and haematological parameters during prolonged treatment. Furthermore, caution is required when Teicoplanin is administered concurrently with other medications known to carry nephrotoxic or ototoxic risks, due to the potential for additive organ damage.

Advertisements

Overdose and Emergency Response

The official regulatory documents state that an overdose of Ортоцид (Teicoplanin) is primarily characterized by the risk of systemic toxicity resulting from drug accumulation. Few cases of massive overdose have been reported, but high exposure can result in documented manifestations affecting major organ systems. The primary toxicity involves the renal system, often presenting as nephrotoxicity and transient elevations of serum creatinine. Hematological abnormalities, such as thrombocytopenia or pancytopenia, are also noted in connection with doses exceeding usual recommendations. Patients with existing renal insufficiency face a heightened risk of accumulation and severe toxicity.

Immediate medical help is required when symptoms of life-threatening events occur, specifically anaphylactic shock or severe skin reactions like Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). The official documentation mandates that treatment must be discontinued immediately, and appropriate emergency measures must be initiated by a physician.

Regarding management, the official labels state there is no specific antidote known for an overdose of Teicoplanin. Management is restricted to symptomatic and supportive treatment. Due to the drug’s pharmacological properties, regulatory information indicates that Teicoplanin is not removed by haemodialysis and is only slowly eliminated by peritoneal dialysis, a critical constraint for managing severe accumulation.

Advertisements

Therapeutic Uses of Ортоцид

Quick Facts

  • Therapeutic Area: Management of chronic inflammatory bowel conditions, specifically mild to moderate Crohn's disease and ulcerative colitis.
  • Key Action: Contributes to the reduction of inflammation in the gastrointestinal tract.
  • Adult Use: Indicated to manage flare-ups and maintain clinical remission in certain conditions.
  • Pediatric Use: Suitable for use in children aged eight years and older for specific indications.

What Ортоцид Treats: Main Uses and Benefits

Ортоцид (budesonide) is a prescription medication utilized to address specific inflammatory conditions within the gastrointestinal system. It is indicated for the treatment of mild to moderate active Crohn's disease that affects the ileum and/or the ascending colon. The treatment aims to support the resolution of acute flare-ups associated with this condition.

This medication is also used in adults for the maintenance of clinical remission from Crohn's disease for a defined period, which may assist in stabilizing the condition following an active phase. Furthermore, certain formulations of the medication are used to manage mild to moderate ulcerative colitis in adults.

Another approved use for a specific formulation is to help reduce the progression of kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of disease worsening. These applications are intended to provide clinical improvement across these therapeutic areas.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ортоцид?

Eligibility for Ортоцид (Budesonide) is strictly defined by regulatory authorities based on a patient's characteristics, age, and pre-existing conditions.

Contraindications and Prohibited Use

Use of the medicine is contraindicated in patients with a known hypersensitivity to budesonide or any of its formulation components. It is also prohibited for patients diagnosed with severe hepatic impairment (Child-Pugh Class C) due to the risk of increased systemic exposure. Specific formulations may also be non-recommended for individuals with rare hereditary disorders like fructose intolerance.

Eligibility by Age and Physiological State

Population Group Eligibility Status Key Restriction
Adults (≥ 18 years) Established Generally approved for all indications.
Children Restricted Use is only established for those ge 8 or ge 11 years, depending on the specific indication.
Pregnancy Avoided Use is avoided unless compelling clinical reasons are present.
Lactation Use with Caution Excreted in breast milk; monitoring of infant growth is recommended.

Patients with moderate hepatic impairment (Child-Pugh Class B) require close monitoring for signs of hypercorticism. Additionally, caution is advised for patients with existing systemic infections, hypertension, diabetes mellitus, or glaucoma.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Ортоцид (Teicoplanin) is primarily structured around pharmacodynamic risks and procedural restrictions detailed in regulatory labeling.

Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions: Medicinal products with known nephrotoxic potential; Medicinal products with known ototoxic potential.
Specific interacting medicines (if explicitly listed): Aminoglycosides, Amphotericin B, Ciclosporin (Cyclosporine), Cisplatin, Furosemide (Frusemide), Ethacrynic acid, Warfarin.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (additive toxicity potential); Physical (incompatibility of solutions); Pharmacokinetic (altered drug clearance in renal impairment).
Timing-based interaction rules (if applicable): Solutions of Teicoplanin and Aminoglycosides must not be mixed before injection or infusion; preparations must be administered separately.
Population-specific interaction notes (if applicable): Renal Impairment: Clearance is reduced, which increases Teicoplanin plasma exposure and may heighten the risk of documented toxicity.

Interaction classifications (high-level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents): Clinically Significant Interaction (Additive Toxicity Risk); Physical Incompatibility (Mandatory Separation Rule).
Regulatory basis: Derived from official Prescribing Information interaction sections and cautions for co-administration.
Interaction-context constraints (as defined in official documents): Applies primarily to concurrent or sequential administration with specified pharmacodynamically-acting substances and to solution preparation procedures.

Resulting interaction structure

Official interaction statements:

  • Co-administration or sequential use with medicinal products recognized as potentially nephrotoxic or ototoxic is restricted by regulatory caution due to the documented potential for additive toxicity.
  • Solutions of Teicoplanin and Aminoglycosides are physically incompatible and must not be mixed prior to injection or infusion; the preparations must be administered separately.
  • The co-administration of Teicoplanin with Warfarin may be associated with an increase in the Prothrombin Time-International Normalized Ratio (PT-INR), an exposure modification requiring monitoring.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product’s interaction structure predominantly by its potential for additive pharmacodynamic toxicity when combined with specific medicinal products, necessitating a formal cautionary restriction. The profile is further structured by a clear, label-mandated physical incompatibility rule requiring timing separation for certain solutions and a note regarding exposure alteration in patients with impaired renal function. The documentation does not cite formal restrictions based on CYP enzyme activity or interactions with food or alcohol.

Advertisements

Mechanism of Action

The mechanism of action for Ортоцид (Teicoplanin) is defined by its ability to prevent the formation of a rigid bacterial structure, a process localized entirely at the cell surface of the pathogen.

Molecular Inhibition of Cell Wall Assembly

Teicoplanin acts as a specific inhibitor by binding tightly to the D-Ala-D-Ala peptide terminus of the essential cell wall precursor ( Lipid II). This binding physically sequesters the precursor, stopping the crucial polymerization and cross-linking enzymes (transglycosylase and transpeptidase) from building a structurally complete cell wall.

Mechanistic Cascade to Cell Lysis

The inability to complete the bacterial cell wall leads to a rapid physiological cascade: the weakened structure cannot withstand the high internal osmotic pressure, causing the bacterial cell to spontaneously rupture (lysis). This outcome is the primary mechanism underlying the drug's bactericidal (cell-killing) effect against susceptible organisms.

Selectivity and Mechanistic Constraints

The drug's large molecular size dictates its mechanism is physiologically limited to Gram-positive bacteria, as it cannot pass the protective outer membrane of Gram-negative pathogens. Furthermore, the mechanism can be severely weakened if the bacteria genetically modify their target to D-Ala-D-Lactate, reducing Teicoplanin's binding strength and constraining its mechanistic action.

Advertisements

Dosage and Administration Information

How to Use Ортоцид (Teicoplanin)

Ортоцид is administered through specialized procedures for the management of serious infections. For systemic treatment, administration is typically via the intravenous (IV) injection/infusion or intramuscular (IM) route. A distinct usage pattern exists for localized gastrointestinal infection, where the drug is given by the oral route.

Administration Scope Description
Dosing Schedule Initial 12-hourly loading phase (3 to 5 doses) followed by a once-daily maintenance dose.
Routes IV or IM for systemic use; Oral for localized C. difficile infection.
Dose Ranges 6 mg/kg or 12 mg/kg for systemic use; 100 mg to 200 mg twice daily for oral use.

The systemic regimen requires administration every 12 hours for an initial loading period before transitioning to a once-daily maintenance dose. For proper preparation, the sterile powder must be reconstituted by gently rolling the vial to avoid foam, as vigorous shaking is prohibited due to the risk of incomplete dose delivery.

High-level adjustments are specified for certain populations. The required dose reduction for patients with renal impairment must only be implemented from the fourth day of treatment onward. Treatment duration is established; it must continue for at least three days after clinical symptoms resolve, but should not exceed four months.

Resulting Procedural Structure The usage protocol is characterized by a standardized two-phase systemic dosing regimen that transitions from 12-hourly loading to once-daily maintenance. The procedural steps strictly govern the method of reconstitution and the rate of intravenous delivery, ensuring that dose reduction for compromised renal function is implemented only after the initial loading period is complete.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ортоцид (Teicoplanin)


Evidence for Use in Serious Gram-Positive Bacterial Infections

Research has explored the use of Ортоцид in individuals with serious systemic infections caused by specific Gram-positive bacteria, including resistant strains like MRSA. Studies primarily consisted of Randomized Controlled Trials (RCTs) designed to explore whether outcomes were comparable to those of the established treatment, such as Vancomycin. Researchers tracked clinical cure (resolution of symptoms) and bacteriological cure (pathogen elimination). Findings from these studies reported patterns where the measured outcomes for Teicoplanin were observed in the study populations.

It is important to note that many of these comparative studies were designed to assess non-inferiority. The design of this research does not allow for definitive conclusions regarding potential superiority. Furthermore, evidence for very specific or rare types of severe systemic infections remains limited by the modest sample sizes of the studies conducted.

Evidence for Use in Deep-Seated Bone and Joint Infections

Studies have also evaluated Ортоцид in patients with deep-seated infections, such as osteomyelitis and septic arthritis. The research examined outcomes related to physical discomfort and functional limitations. The evidence base includes formal clinical trials as well as data derived from observational settings, often requiring prolonged treatment durations (four or more weeks).

Findings indicate that research highlights changes measured during the study period, tracking both clinical response and sustained elimination of the bacteria. However, a key limitation noted in the research is the challenge of ensuring that measured drug levels are appropriate for the severity and location of the infection, particularly within bone and joint tissues.

What is Still Uncertain About the Research for Ортоцид

Several limitations and uncertainties exist within the current research evidence. First, the research often focuses on whether the drug was comparable to existing treatments. Second, evidence quality varies across studies, and some trials suffer from modest sample sizes. Finally, for deep-seated infections, research is ongoing regarding approaches to achieve and maintain drug concentrations in hard-to-reach infected tissues. The research observed the drug’s processing by the kidneys, particularly in individuals with kidney issues.

Key Studies & References

  1. Efficacy of oral Teicoplanin versus oral Vancomycin for Clostridioides difficile infection: Clinical trial data review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ортоцид (FAQ)


Q: How quickly do people usually start to feel the effects of Ортоцид?

A: Ortozid (Teicoplanin) is prescribed using an initial, more frequent 'loading dose' strategy. This method is specifically designed to quickly raise the level of medicine in the bloodstream to a therapeutic concentration. The medicine has a long elimination profile, which is characteristic of this treatment.

Q: Does Ортоцид work instantly or does it take time to build up in the system?

A: The medicine is administered using an initial set of frequent doses, known as a loading phase. This procedure is designed to help the medicine build up a target therapeutic level in the body relatively quickly. Once this target level is reached, the treatment schedule is usually adjusted to a less frequent administration.

Q: Are there any specific foods or drinks that should be limited with Ортоцид?

A: Official drug labels from regulatory authorities do not cite any formal restrictions or documented interactions with specific foods or drinks. The systemic form is administered directly, and the oral form acts locally in the gut, meaning food intake is not generally relevant.

Q: Is it true that Ортоцид can affect sleep patterns?

A: Official safety data lists central nervous system effects, such as headache and dizziness, as uncommon adverse reactions. Specific changes to sleep patterns, such as difficulty sleeping (insomnia) or excessive sleepiness (somnolence), are not explicitly listed in the common or uncommon side effect categories in the official product information. Any experienced side effects, such as dizziness, should be discussed with the prescribing healthcare provider.

Q: Do older adults (seniors) need to take a different amount of Ортоцид?

A: Official guidelines state that a dose adjustment is generally not required for older adults simply based on age. However, the need for adjustment is primarily determined by existing kidney function, as detailed in the regulatory information, due to the drug's processing by the kidneys.

Q: Has the drug Ортоцид been approved in major regions like the US or Europe?

A: Ortozid (Teicoplanin) has established regulatory approval and is actively monitored by government bodies in many major international regions, including those in the European Union.

Q: Why is it important to complete the full course of treatment with Ортоцид?

A: The duration of treatment is regulated and must continue for a specific time, often until clinical symptoms have resolved for at least three days. The full prescribed duration is important to meet the therapeutic goal of pathogen elimination and fully address the underlying infection.

Q: Does taking Ортоцид with food change how it works?

A: For the systemic form (IV or IM), food intake is not relevant as the medicine is administered directly into the bloodstream. The oral form of the medicine is designed not to be absorbed into the bloodstream but rather to act locally in the gut, making its effectiveness separate from food intake.

Q: Can Ортоцид be split or crushed to make it easier to swallow?

A: The systemic form of the drug is a sterile powder intended only for professional reconstitution and injection/infusion. The oral formulation is for a specific, localized infection. Modification by crushing or splitting is not generally advised, given the strict requirements for preparation and administration.

Q: Can Ортоцид be used for things other than what's on the label?

A: Regulatory documents specify that the medicine’s use is limited to its officially approved indications (conditions) and patient populations. This information is found in the official product labeling.

Q: Is Ортоцид used for pain relief?

A: The official indications for Ortozid (Teicoplanin) focus exclusively on treating serious, specific bacterial infections. Pain relief is not listed as a specified use or indication for this medicine.

Q: What is the difference between Ортоцид and [Commonly Misspelled Name]?

A: The active substance in Ortozid is Teicoplanin, which is officially classified as a glycopeptide antibiotic. This classification defines its specific structure and targeted mechanism of action.

Q: What should be done if a user forgets to take a dose of Ортоцид?

A: A missed dose for the injection/infusion form is managed by the patient’s healthcare provider. For the oral form, instructions typically advise taking the dose as soon as it's remembered, unless it is almost time for the next dose. Official instructions caution against taking a double dose.

Q: Is it normal to feel a little dizzy after starting Ортоцид?

A: Official safety information classifies dizziness as an uncommon adverse effect. This means it is reported in a small percentage of patients—specifically, 1 to 10 out of every 1,000 users. If this or any side effect is experienced, it should be discussed with a healthcare provider.

Q: Can people with a history of liver issues use Ортоцид?

A: Caution is generally advised for patients with existing liver issues, and the drug label requires close monitoring of liver function during the course of treatment. Severe hepatic impairment (liver failure) is strictly listed as a prohibited use (contraindication) for this medicine.

Q: What kind of medical history prevents someone from using Ортоцид?

A: The medicine is strictly prohibited (contraindicated) for patients with a known hypersensitivity (allergy) to the drug or any of its formulation components. It is also prohibited for patients with severe hepatic impairment.

Q: Are there any long-term research studies about the use of Ортоцид?

A: Research has included studies involving prolonged treatment durations, particularly for infections in difficult-to-treat areas like bone and joints. Studies have also conducted follow-ups on drug concentrations after treatment stops to understand the medicine’s persistence in the body.

Q: What do clinical trials say about the general expectation of effect with Ортоцид?

A: Clinical trials for this drug were often designed to determine if its effectiveness in achieving a clinical cure was comparable to (non-inferior to) other existing treatments for serious Gram-positive infections. The official data focuses on measured outcomes related to symptom resolution and pathogen elimination.

Q: Is there a generic version of Ортоцид available?

A: Teicoplanin is the active ingredient in Ortozid. Generic versions of the drug containing Teicoplanin are available in some regions, subject to local regulatory approvals.

Q: What happens if someone accidentally takes too much Ортоцид?

A: In the event that an overdose is suspected, official instructions mandate immediate contact with a healthcare professional or emergency services. Immediate medical evaluation and care are required, as is the case with most medications of this type.

Q: Are there restrictions on driving or operating machinery while on Ортоцид?

A: Official warnings advise that the drug may affect the ability to drive or operate complex machinery. This caution is due to potential side effects that include headache and dizziness, which could impair judgment or motor skills.

Q: Is it possible to be allergic to the inactive ingredients in Ортоцид?

A: The contraindication for use includes a known hypersensitivity (allergy) not just to the active ingredient, but to any of the other components in the medicine's formulation, including the inactive ingredients.

Q: How long does Ортоцид stay in your system after the last dose?

A: The drug has a very long elimination half-life, which means the substance is processed and removed from the body slowly. Official data shows that the medicine can remain detectable in the body for an extended period, potentially several days following the last dose.

Q: What are the most common reasons patients stop taking Ортоцид?

A: The official safety profile highlights that the drug is typically discontinued if a patient experiences a serious adverse reaction, such as a severe allergy, or develops severe toxicity to the kidneys (nephrotoxicity) or ears (ototoxicity).

Q: Is Ортоцид a controlled substance?

A: The drug is officially classified as a prescription-only (Rx) medication. It is a glycopeptide antibiotic and is not listed as a federally controlled substance in the major regulatory classifications.

Q: Can Ортоцид be taken with other maintenance medications for chronic conditions?

A: Co-administration with other medicines is primarily restricted by the potential for additive toxicity. Official documents caution against taking this drug concurrently with any medication that is known to potentially cause damage to the kidneys or the ears, which may include certain medications used for chronic conditions.

Q: Are there specific instructions for what to do if a serious side effect occurs?

A: In the event of a severe reaction, such as anaphylactic shock or a severe skin reaction, official instructions mandate the immediate discontinuation of the medicine. The patient must receive appropriate emergency medical measures, which should be guided by a healthcare professional.

Q: Why is it important to tell the prescribing doctor about all supplements when starting Ортоцид?

A: Official caution is required when using this medicine concurrently with any product that has the potential to cause toxicity, especially to the kidneys or ears. Because supplements may contain ingredients that can interact or cause organ stress, reporting all substances is necessary for patient safety.

Advertisements

How should Ортоцид be stored and disposed of?

How to Store and Dispose of Ortotzid (Teicoplanin)

Ortotzid (Teicoplanin) must be stored and handled according to specific regulatory conditions to maintain its integrity.


Storage Conditions

The unopened vial of dry powder must be stored in its original, tightly closed container at a temperature below 25°C (77°F). The medication must be kept out of the sight and reach of children.

Once the powder is reconstituted, the resulting solution has limited stability. The prepared solution is stable for 24 hours when stored under refrigeration (2°C to 8°C) and should ideally be used immediately.


Disposal Instructions

Unused or expired Ortotzid must not be disposed of via wastewater or regular household trash. Disposal must be carried out in accordance with local regulations, typically requiring the product to be taken to an authorised hazardous or special waste collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ортоцид found in:

A-Z Index: